Wedbush Forecasts Lower Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Wedbush lowered their Q1 2026 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $1.10 for the quarter, down from their prior forecast of $1.31. Wedbush currently has a “Outperform” rating on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.58 EPS and Q4 2026 earnings at $1.68 EPS.

A number of other research firms have also recently commented on NBIX. Needham & Company LLC lifted their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright lowered their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a report on Tuesday, April 22nd. UBS Group upped their price objective on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore ISI lowered their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Finally, BMO Capital Markets increased their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a “market perform” rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $162.00.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $117.52 on Thursday. The stock’s 50 day moving average price is $106.18 and its 200 day moving average price is $121.81. The firm has a market cap of $11.63 billion, a P/E ratio of 35.72, a PEG ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a 1 year low of $84.23 and a 1 year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.20 EPS.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently modified their holdings of the business. OneDigital Investment Advisors LLC grew its stake in Neurocrine Biosciences by 2.1% during the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company’s stock worth $575,000 after buying an additional 87 shares during the last quarter. HighPoint Advisor Group LLC grew its position in Neurocrine Biosciences by 4.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company’s stock worth $334,000 after acquiring an additional 96 shares during the last quarter. Huntington National Bank increased its holdings in Neurocrine Biosciences by 73.5% during the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after purchasing an additional 97 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Neurocrine Biosciences by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company’s stock worth $3,836,000 after purchasing an additional 100 shares in the last quarter. Finally, Utah Retirement Systems grew its holdings in shares of Neurocrine Biosciences by 0.6% during the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company’s stock worth $2,264,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Julie Cooke sold 700 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $118.28, for a total value of $82,796.00. Following the completion of the transaction, the insider now owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. This represents a 3.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.37, for a total value of $269,173.38. Following the sale, the director now owns 519,074 shares in the company, valued at $61,442,789.38. This represents a 0.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,907 shares of company stock valued at $4,935,982 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences declared that its board has initiated a share buyback plan on Friday, February 21st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to purchase up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.